Bart L Haagmans

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/584421/bart-l-haagmans-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

29,865 264 170 74 h-index g-index citations papers 8.75 37,398 12.1 290 L-index ext. citations avg, IF ext. papers

#	Paper	IF	Citations
264	SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination <i>Cell Research</i> , 2022 ,	24.7	28
263	Middle East respiratory syndrome coronavirus infection in camelids Veterinary Pathology, 2022, 30098	5 <u>8</u> 811	069120
262	Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients <i>Science Immunology</i> , 2022 , 7, eabo2202	28	48
261	Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets <i>MBio</i> , 2022 , e0383121	7.8	0
260	Defining the risk of SARS-CoV-2 variants on immune protection <i>Nature</i> , 2022 ,	50.4	7
259	Spreading of SARS-CoV-2 from hamsters to humans <i>Lancet, The</i> , 2022 , 399, 1027-1028	40	1
258	Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns <i>PLoS Pathogens</i> , 2022 , 18, e1010340	7.6	2
257	SARS-CoV-2 pathogenesis <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	30
256	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern <i>Science Immunology</i> , 2022 , eabp9312	28	5
255	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters. <i>Nature Communications</i> , 2022 , 13,	17.4	5
254	Interferon-2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19. <i>Journal of Clinical Immunology</i> , 2021 , 1	5.7	5
253	Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens. <i>PLoS ONE</i> , 2021 , 16, e0259165	3.7	10
252	Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021. <i>Biologicals</i> , 2021 , 74, 10-15	1.8	
251	Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. <i>Science</i> , 2021 , 371, 1379-1382	33.3	72
250	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. <i>Cell</i> , 2021 , 184, 1188-1200.e19	56.2	68
249	A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. <i>Nature Communications</i> , 2021 , 12, 1715	17.4	60
248	Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation 2021 ,		2

(2021-2021)

247	Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation. <i>ELife</i> , 2021 , 10,	8.9	42
246	A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice. <i>European Journal of Immunology</i> , 2021 , 51, 1774-1784	6.1	9
245	High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021 , 223, 1512-1521	7	21
244	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021 , 12, 3189	17.4	76
243	Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures. <i>MSphere</i> , 2021 , 6,	5	5
242	SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. <i>Science Immunology</i> , 2021 , 6,	28	185
241	Advancing lung organoids for COVID-19 research. DMM Disease Models and Mechanisms, 2021, 14,	4.1	18
240	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021 , 223, 2020-2028	7	16
239	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	27
238	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <i>PLoS Pathogens</i> , 2021 , 17, e1009282	7.6	23
237	Science, not speculation, is essential to determine how SARS-CoV-2 reached humans. <i>Lancet, The</i> , 2021 , 398, 209-211	40	7
236	The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues. <i>Viruses</i> , 2021 , 13,	6.2	11
235	Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	6
234	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses. <i>Nature Communications</i> , 2021 , 12, 5498	17.4	15
233	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021 , 27, 1518-1524	50.5	49
232	Animal models of SARS-CoV-2 transmission. <i>Current Opinion in Virology</i> , 2021 , 50, 8-16	7.5	11
231	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. <i>One Health</i> , 2021 , 13, 1003	73 6	4
230	An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of human alveolar type II-like cells. <i>EMBO Journal</i> , 2021 , 40, e105912	13	67

229	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). <i>Nature Communications</i> , 2021 , 12, 267	17.4	333
228	Susceptibility of rabbits to SARS-CoV-2. Emerging Microbes and Infections, 2021, 10, 1-7	18.9	70
227	SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. <i>ELife</i> , 2021 , 10,	8.9	64
226	A human monoclonal antibody blocking SARS-CoV-2 infection. <i>Nature Communications</i> , 2020 , 11, 2251	17.4	685
225	Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV. <i>Emerging Microbes and Infections</i> , 2020 , 9, 1080-1091	18.9	9
224	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. <i>Science</i> , 2020 , 369, 643-650	33.3	724
223	Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1478-1488	10.2	1055
222	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020 , 11, 3436	17.4	224
221	SARS-CoV-2 is transmitted via contact and via the air between ferrets. <i>Nature Communications</i> , 2020 , 11, 3496	17.4	271
220	The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. <i>Nature Microbiology</i> , 2020 , 5, 536-544	26.6	3797
219	Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. <i>Lancet, The</i> , 2020 , 395, e42-e43	40	133
218	SARS-CoV-2 productively infects human gut enterocytes. <i>Science</i> , 2020 , 369, 50-54	33.3	882
217	Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. <i>EBioMedicine</i> , 2020 , 55, 102743	8.8	201
216	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. <i>Emerging Infectious Diseases</i> , 2020 , 26, 1024-1027	10.2	13
215	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020 , 20, 827-83	38 ^{25.5}	74
214	Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. <i>Science Immunology</i> , 2020 , 5,	28	554
213	Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	117
212	AuthorsPresponse: Plenty of coronaviruses but no SARS-CoV-2. <i>Eurosurveillance</i> , 2020 , 25,	19.8	1

(2019-2020)

211	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. <i>Scientific Reports</i> , 2020 , 10, 21894	4.9	12
210	Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets 2020 ,		4
209	Animal models for COVID-19. <i>Nature</i> , 2020 , 586, 509-515	50.4	377
208	Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 2020 , 25,	19.8	4027
207	Assessing the extent of SARS-CoV-2 circulation through serological studies. <i>Nature Medicine</i> , 2020 , 26, 1171-1172	50.5	34
206	Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. <i>Science</i> , 2020 , 368, 1012-1015	33.3	596
205	Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya. <i>Viruses</i> , 2020 , 12,	6.2	7
204	Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections. <i>Emerging Infectious Diseases</i> , 2019 , 25, 1868-1877	10.2	65
203	Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus. <i>Emerging Infectious Diseases</i> , 2019 , 25, 1878-1883	10.2	12
202	Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors. <i>Journal of Virology</i> , 2019 , 93,	6.6	27
201	Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits. Viruses, 2019, 11,	6.2	8
200	Host Determinants of MERS-CoV Transmission and Pathogenesis. <i>Viruses</i> , 2019 , 11,	6.2	39
199	Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. <i>Emerging Microbes and Infections</i> , 2019 , 8, 516-530	18.9	86
198	ADAR1: "Editor-in-Chief" of Cytoplasmic Innate Immunity. Frontiers in Immunology, 2019, 10, 1763	8.4	70
197	Failure to detect MERS-CoV RNA in urine of naturally infected dromedary camels. <i>Zoonoses and Public Health</i> , 2019 , 66, 437-438	2.9	8
196	Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein. <i>Emerging Microbes and Infections</i> , 2019 , 8, 1593-1603	18.9	19
195	MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017. <i>Emerging Infectious Diseases</i> , 2019 , 25, 2333-2335	10.2	15
194	Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. <i>Scientific Reports</i> , 2019 , 9, 18892	4.9	8

193	Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas. <i>Transboundary and Emerging Diseases</i> , 2019 , 66, 831-841	4.2	12
192	DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients. <i>Clinical Infectious Diseases</i> , 2018 , 66, 45-	5 ³ 1.6	63
191	Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4. <i>Scientific Reports</i> , 2018 , 8, 9778	4.9	25
190	Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection. <i>Science Advances</i> , 2018 , 4, eaas9667	14.3	55
189	Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels. <i>One Health</i> , 2018 , 5, 65-68	7.6	30
188	Multihospital Outbreak of a Middle East Respiratory Syndrome Coronavirus Deletion Variant, Jordan: A Molecular, Serologic, and Epidemiologic Investigation. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy095	1	12
187	MERS-coronavirus: From discovery to intervention. <i>One Health</i> , 2017 , 3, 11-16	7.6	34
186	Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia. <i>Journal of Medical Virology</i> , 2017 , 89, 1300-1303	19.7	8
185	Virus genomes reveal factors that spread and sustained the Ebola epidemic. <i>Nature</i> , 2017 , 544, 309-315	5 50.4	238
184	Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches. <i>Current Opinion in Virology</i> , 2017 , 23, 49-58	7.5	47
183	Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013-2014: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 2017 , 215, 1702-1705	7	31
182	Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus. <i>Emerging Infectious Diseases</i> , 2017 , 23, 232-240	10.2	71
181	Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E8508-E8517	11.5	216
180	Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells. <i>MSphere</i> , 2017 , 2,	5	62
179	Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Nalle Patients. <i>Scientific Reports</i> , 2017 , 7, 4688	4.9	14
178	Tissue Distribution of the MERS-Coronavirus Receptor in Bats. <i>Scientific Reports</i> , 2017 , 7, 1193	4.9	28
177	A novel hepatitis B virus subgenotype D10 circulating in Ethiopia. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 163-173	3.4	11

(2015-2016)

175	Intrathecal CD4(+) and CD8(+) T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. <i>European Journal of Immunology</i> , 2016 , 46, 347-53	6.1	9
174	Cross host transmission in the emergence of MERS coronavirus. <i>Current Opinion in Virology</i> , 2016 , 16, 55-62	7.5	61
173	Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection. <i>Journal of Virology</i> , 2016 , 90, 4394-401	6.6	55
172	Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels. <i>Journal of Virology</i> , 2016 , 90, 4838-4842	6.6	82
171	An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. <i>Science</i> , 2016 , 351, 77-81	33.3	182
170	The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction. <i>OIE Revue Scientifique Et Technique</i> , 2016 , 35, 905-911	2.5	7
169	Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization. <i>Journal of General Virology</i> , 2016 , 97, 2180-2186	4.9	10
168	Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015. <i>Emerging Infectious Diseases</i> , 2016 , 22, 716-9	10.2	32
167	MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic. <i>Emerging Infectious Diseases</i> , 2016 , 22, 1129-31	10.2	53
166	Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia. <i>Journal of Medical Virology</i> , 2016 , 88, 1035-43	19.7	13
165	Miscarriage Associated with Zika Virus Infection. New England Journal of Medicine, 2016, 375, 1002-4	59.2	115
164	Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. <i>Journal of Virology</i> , 2015 , 89, 6131-5	6.6	71
163	High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. <i>Infection Ecology and Epidemiology</i> , 2015 , 5, 28305	4.3	61
162	Genome sequence of enterovirus D68 and clinical disease, Thailand. <i>Emerging Infectious Diseases</i> , 2015 , 21, 384	10.2	9
161	Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013-2014. Emerging Infectious Diseases, 2015 , 21, 1422-5	10.2	63
160	Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009-2013. <i>Emerging Infectious Diseases</i> , 2015 , 21, 1205-8	10.2	37
159	Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. <i>Journal of Virology</i> , 2015 , 89, 4809-17	6.6	32
158	Reliable typing of MERS-CoV variants with a small genome fragment. <i>Journal of Clinical Virology</i> , 2015 , 64, 83-7	14.5	22

157	Pathogenesis of Middle East respiratory syndrome coronavirus. <i>Journal of Pathology</i> , 2015 , 235, 175-84	9.4	104
156	ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. <i>Journal of Virology</i> , 2015 , 89, 4434-48	6.6	83
155	Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015. <i>Eurosurveillance</i> , 2015 , 20,	19.8	12
154	Identification of protein receptors for coronaviruses by mass spectrometry. <i>Methods in Molecular Biology</i> , 2015 , 1282, 165-82	1.4	10
153	Updated phylogenetic analysis of arenaviruses detected in boid snakes. <i>Journal of Virology</i> , 2014 , 88, 1399-400	6.6	11
152	Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infectious Diseases, The, 2014 , 14, 140-5	25.5	487
151	Exploring the potential of next-generation sequencing in detection of respiratory viruses. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 3722-30	9.7	76
150	Novel divergent nidovirus in a python with pneumonia. <i>Journal of General Virology</i> , 2014 , 95, 2480-2485	4.9	30
149	Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. <i>Journal of Virology</i> , 2014 , 88, 1834-8	6.6	124
148	Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2014 , 44, 528-32	14.3	90
147	The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. <i>Journal of Comparative Pathology</i> , 2014 , 151, 83-112	1	113
146	Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. <i>Eurosurveillance</i> , 2014 , 19,	19.8	117
145	Metagenomic survey for viruses in Western Arctic caribou, Alaska, through iterative assembly of taxonomic units. <i>PLoS ONE</i> , 2014 , 9, e105227	3.7	16
144	Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. <i>PLoS Pathogens</i> , 2014 , 10, e1004502	7.6	261
143	New viruses in idiopathic human diarrhea cases, the Netherlands. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1218-22	10.2	68
142	Geographic distribution of MERS coronavirus among dromedary camels, Africa. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1370-4	10.2	145
141	Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. <i>Emerging Infectious Diseases</i> , 2014 , 20, 1339-42	10.2	140
140	Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. <i>Journal of Medical Visional</i> 2014, 86, 177, 85	19.7	3

(2013-2014)

139	Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. <i>Vaccine</i> , 2014 , 32, 5975-82	4.1	106
138	Neutralizing the MERS coronavirus threat. <i>Science Translational Medicine</i> , 2014 , 6, 235fs19	17.5	5
137	Membrane ectopeptidases targeted by human coronaviruses. Current Opinion in Virology, 2014 , 6, 55-60	7.5	28
136	MERS: emergence of a novel human coronavirus. Current Opinion in Virology, 2014 , 5, 58-62	7.5	127
135	Presence of anti-interferon antibodies is not associated with non-response to pegylated interferon treatment in chronic hepatitis B. <i>Antiviral Therapy</i> , 2014 , 19, 423-7	1.6	1
134	Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa. <i>Emerging Infectious Diseases</i> , 2014 , 20,	10.2	4
133	Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. <i>Lancet Infectious Diseases, The</i> , 2013 , 13, 859-66	25.5	523
132	The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. <i>Journal of Virology</i> , 2013 , 87, 9379-83	6.6	171
131	Spiking the MERS-coronavirus receptor. <i>Cell Research</i> , 2013 , 23, 1069-70	24.7	21
130	Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. <i>Journal of Virology</i> , 2013 , 87, 11950-4	6.6	111
129	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 13109-13	11.5	330
128	Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. <i>Journal of General Virology</i> , 2013 , 94, 1206-1210	4.9	60
127	Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. <i>Nature</i> , 2013 , 495, 251-4	50.4	1362
126	MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-treatment. <i>Journal of General Virology</i> , 2013 , 94, 1749-1760	4.9	258
125	Novel cyclovirus in human cerebrospinal fluid, Malawi, 2010-2011. <i>Emerging Infectious Diseases</i> , 2013 , 19,	10.2	57
124	Identification of multiple novel viruses, including a parvovirus and a hepevirus, in feces of red foxes. <i>Journal of Virology</i> , 2013 , 87, 7758-64	6.6	82
123	T-Cell tropism of simian varicella virus during primary infection. <i>PLoS Pathogens</i> , 2013 , 9, e1003368	7.6	38
122	Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. <i>PLoS Pathogens</i> , 2013 , 9, e1003196	7.6	141

121	Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. <i>Journal of Virology</i> , 2013 , 87, 13892-9	6.6	72
120	Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 238-	-4 ² 2 ⁷	30
119	Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. <i>Eurosurveillance</i> , 2013 , 18, 20662	19.8	154
118	Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection. <i>PLoS ONE</i> , 2013 , 8, e56991	3.7	11
117	The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. <i>PLoS ONE</i> , 2013 , 8, e69127	3.7	105
116	Identification and characterization of two novel viruses in ocular infections in reindeer. <i>PLoS ONE</i> , 2013 , 8, e69711	3.7	11
115	Metagenomic analysis of the ferret fecal viral flora. <i>PLoS ONE</i> , 2013 , 8, e71595	3.7	59
114	Specific serology for emerging human coronaviruses by protein microarray. <i>Eurosurveillance</i> , 2013 , 18, 20441	19.8	76
113	Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. <i>MBio</i> , 2012 , 3,	7.8	632
112	Metagenomic analysis of the viral flora of pine marten and European badger feces. <i>Journal of Virology</i> , 2012 , 86, 2360-5	6.6	91
111	Picobirnaviruses in the human respiratory tract. <i>Emerging Infectious Diseases</i> , 2012 , 18, 1539-40	10.2	27
110	Calicivirus from novel Recovirus genogroup in human diarrhea, Bangladesh. <i>Emerging Infectious Diseases</i> , 2012 , 18, 1192-5	10.2	24
109	Novel hepatitis E virus in ferrets, the Netherlands. <i>Emerging Infectious Diseases</i> , 2012 , 18, 1369-70	10.2	144
108	Continuous interferon-2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. <i>Antiviral Therapy</i> , 2012 , 17, 509-17	1.6	3
107	Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. <i>G3: Genes, Genomes, Genetics</i> , 2012 , 2, 213-21	3.2	68
106	Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. <i>MBio</i> , 2012 , 3,	7.8	154
105	Impact of obesity on the bioavailability of peginterferon-Pa and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. <i>PLoS ONE</i> , 2012 , 7, e37521	3.7	13
104	Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. <i>Eurosurveillance</i> , 2012 , 17,	19.8	273

103	IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. <i>Journal of Hepatology</i> , 2011 , 55, 980-8	13.4	92
102	Enteric coronavirus in ferrets, The Netherlands. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1570-1	10.2	17
101	Distinct severe acute respiratory syndrome coronavirus-induced acute lung injury pathways in two different nonhuman primate species. <i>Journal of Virology</i> , 2011 , 85, 4234-45	6.6	61
100	Twice-weekly pegylated interferon-Pa and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. <i>Aids</i> , 2011 , 25, 1179-87	3.5	15
99	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. <i>PLoS ONE</i> , 2011 , 6, e17232	3.7	120
98	A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. <i>PLoS ONE</i> , 2011 , 6, e18995	3.7	26
97	Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?. <i>Clinical Infectious Diseases</i> , 2010 , 50, e22-5	11.6	2
96	Exacerbated innate host response to SARS-CoV in aged non-human primates. <i>PLoS Pathogens</i> , 2010 , 6, e1000756	7.6	247
95	2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-FAND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION. <i>Journal of Hepatology</i> , 2010 , 52, S468	13.4	6
94	Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. <i>Journal of Hepatology</i> , 2010 , 53, 460-7	13.4	30
93	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010 , 22, 1443-8	2.2	1
92	SARS 2009 , 671-683		2
91	Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. <i>Aids</i> , 2009 , 23, 2439-50	3.5	15
90	Unraveling the complexities of the interferon response during SARS-CoV infection. <i>Future Virology</i> , 2009 , 4, 71-78	2.4	14
89	Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. <i>Journal of Virology</i> , 2009 , 83, 7062-74	6.6	132
88	The application of genomics to emerging zoonotic viral diseases. <i>PLoS Pathogens</i> , 2009 , 5, e1000557	7.6	43
87	Virogenomics: the virus-host interaction revisited. <i>Current Opinion in Microbiology</i> , 2008 , 11, 461-6	7.9	7
86	ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2008 , 42, 160-4	14.5	9

85	DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-alpha and TNF-alpha. <i>Virus Research</i> , 2008 , 135, 64-7	1 ^{6.4}	55
84	Complete genome analysis of hepatitis C virus subtypes 6t and 6u. <i>Journal of General Virology</i> , 2008 , 89, 1276-1281	4.9	16
83	Severe acute respiratory syndrome (SARS) vaccines 2008 , 1301-1306		
82	HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). <i>Gastroenterology</i> , 2007 , 133, 1132-43	13.3	55
81	The emerging role of ACE2 in physiology and disease. <i>Journal of Pathology</i> , 2007 , 212, 1-11	9.4	282
80	Functional genomics highlights differential induction of antiviral pathways in the lungs of SARS-CoV-infected macaques. <i>PLoS Pathogens</i> , 2007 , 3, e112	7.6	53
79	Characterization of hepatitis C virus deletion mutants circulating in chronically infected patients. Journal of Virology, 2007 , 81, 12496-503	6.6	38
78	Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. <i>Aids</i> , 2007 , 21, 1855-65	3.5	30
77	Modelling of Early Viral Kinetics and Pegylated Interferon-₽b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2007 , 12, 1285-1294	1.6	8
76	Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. <i>Virology</i> , 2006 , 353, 474-81	3.6	93
75	Coronaviruses and their therapy. Antiviral Research, 2006, 71, 397-403	10.8	36
74	Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. <i>Hepatology</i> , 2006 , 44, 721-7	11.2	57
73	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. <i>Hepatology</i> , 2006 , 44, 1617-25	11.2	177
72	Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5Puntranslated regions. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 3969-74	9.7	45
71	Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. <i>Journal of Virology</i> , 2006 , 80, 7569-77	6.6	124
70	AuthorsPResponse to Hogan. <i>PLoS Medicine</i> , 2006 , 3, e415	11.6	78
69	Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2006 , 194, 895-903	7	190
68	Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. <i>New England Journal of Medicine</i> , 2006 , 354, 1323-4	59.2	39

(2002-2006)

67	Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. <i>Gastroenterology</i> , 2006 , 131, 1452-62	13.3	112
66	Nonhuman primate models for SARS. <i>PLoS Medicine</i> , 2006 , 3, e194	11.6	19
65	Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses. <i>Vaccine</i> , 2005 , 23, 1343-50	4.1	4
64	Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. <i>European Urology</i> , 2005 , 48, 153-61	10.2	30
63	Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN-alpha/beta. <i>Journal of General Virology</i> , 2004 , 85, 795-803	4.9	19
62	Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection. <i>Journal of Viral Hepatitis</i> , 2004 , 11, 342-8	3.4	8
61	Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. <i>Nature Medicine</i> , 2004 , 10, 290-3	50.5	329
60	Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. <i>Lancet, The</i> , 2004 , 363, 2139-41	40	228
59	The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain. <i>Virology</i> , 2003 , 312, 395-406	3.6	54
58	Comparative study of different methods to genotype hepatitis C virus type 6 variants. <i>Journal of Virological Methods</i> , 2003 , 109, 195-201	2.6	53
57	A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. <i>Journal of Virological Methods</i> , 2003 , 110, 201-9	2.6	152
56	Virology: SARS virus infection of cats and ferrets. <i>Nature</i> , 2003 , 425, 915	50.4	451
55	Rat testicular germ cells and Sertoli cells release different types of bioactive transforming growth factor beta in vitro. <i>Reproductive Biology and Endocrinology</i> , 2003 , 1, 3	5	14
54	Molecular epidemiology of gibbon hepatitis B virus transmission. <i>Journal of General Virology</i> , 2003 , 84, 147-155	4.9	27
53	Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. <i>Journal of Infectious Diseases</i> , 2003 , 188, 1528-32	7	15
52	SARS virus infection of cats and ferrets. <i>Nature</i> , 2003 , 425, 915-915	50.4	2
51	Protective antiviral immune responses to pseudorabies virus induced by DNA vaccination using dimethyldioctadecylammonium bromide as an adjuvant. <i>Journal of Virology</i> , 2002 , 76, 10540-5	6.6	25
50	DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2B patients treated with PEG-interferon-alfa-2a and ribavirin. <i>Journal of Hepatology</i> , 2002 , 36, 121	13.4	6

49	Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus. Journal of General Virology, 2002 , 83, 1-10	4.9	34
48	A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection. <i>Veterinary Immunology and Immunopathology</i> , 2000 , 74, 121-36	2	35
47	Corrigendum to "A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection". <i>Veterinary Immunology and Immunopathology</i> , 2000 , 75, 161-2	2	О
46	Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D. <i>Vaccine</i> , 1999 , 17, 1264-71	4.1	27
45	Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs. <i>Veterinary Immunology and Immunopathology</i> , 1998 , 66, 113-26	2	66
44	Persistence and evolution of feline coronavirus in a closed cat-breeding colony. <i>Virology</i> , 1997 , 234, 349)- <u>6</u> .8	104
43	Apoptosis and T-cell depletion during feline infectious peritonitis. <i>Journal of Virology</i> , 1996 , 70, 8977-83	36.6	63
42	Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. Journal of Virology, 1994 , 68, 2297-304	6.6	35
41	Suppression of rat cytomegalovirus replication by antibodies against gamma interferon. <i>Journal of Virology</i> , 1994 , 68, 2305-12	6.6	18
40	Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. <i>Blood</i> , 1994 , 83, 446-451	2.2	3
39	Tumor necrosis factor alpha levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection. <i>Veterinary Immunology and Immunopathology</i> , 1992 , 35, 61-9	2	23
38	Pneumococcal conjugate vaccines. <i>Immunology Letters</i> , 1991 , 30, 267-74	4.1	25
37	Protection of rats against pseudorabies virus infection by gamma-interferon. <i>Experimental Biology and Medicine</i> , 1989 , 192, 47-55	3.7	3
36	SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium		6
35	SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)		2
34	Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients		7
33	Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.		3
32	The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface		1

31	A human monoclonal antibody blocking SARS-CoV-2 infection	53
30	Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model	27
29	SARS-CoV-2 specific antibody responses in COVID-19 patients	88
28	Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome	39
27	SARS-CoV-2 is transmitted via contact and via the air between ferrets	24
26	Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens	28
25	Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment	27
24	SARS-CoV-2 Productively Infects Human Gut Enterocytes	41
23	Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability	41
22	Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants	109
21	Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands	10
20	SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model	16
19	Susceptibility of rabbits to SARS-CoV-2	11
18	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins	2
17	The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells	5
16	Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies	14
15	Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein	9
14	The post-acute phase of SARS-CoV-2 infection in two macaques species is associated with signs of ongoing virus replication and pathology in pulmonary and extrapulmonary tissues	5

13	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection		1
12	3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements		2
11	The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune respon	ises	7
10	A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses	5	2
9	Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7		7
8	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test		1
7	Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation		4
6	Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vacci	inatio	n6
5	Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers		23
4	An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants		1
3	Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants		7
2	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters		1
1	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> ,	50.5	2